Remarkably, a high-throughput quantitative analysis of 27 biomarkers of metabolism—using Reverse Phase Protein Array (RPPA) technology, in a cohort of 128 tumors and the corresponding paired NAT of patients bearing lung adenocarcinomas (LUAD)— confirmed that the BEC index is significantly diminished in the carcinomas, suggesting that OXPHOS activity is limited in LUAD [20], in agreement with previous reports [16,23,145]. The gene discussed is BRD2; the disease is carcinoma.